GMAB
$25.10-0.63 (-2.45%)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Recent News
Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate
Genmab and Lundbeck shared new clinical progress for amlenetug at the AD/PD 2026 conference. Amlenetug is a human monoclonal antibody targeting synucleinopathies such as multiple system atrophy and Parkinson’s disease. The update focused on emerging clinical data and development advances for this investigational neurological therapy. For investors tracking CPSE:GMAB, the latest amlenetug update adds additional detail to Genmab’s work in severe neurological diseases. The company’s shares...
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches
Genmab A/S (NASDAQ:GMAB) executives highlighted a “very strong year” in 2025 and outlined a catalyst-heavy 2026 that could set up multiple launches in 2027, according to remarks made by Chief Financial Officer Anthony Pagano and Chief Commercial Officer Brad Bailey at a Leerink Partners event hosted
Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab
Genmab A/S (NASDAQ:GMAB) executives outlined a slate of late-stage clinical catalysts expected in 2026, highlighting multiple potentially registrational readouts across three key programs: EPKINLY, Rina-S and petosemtamab. Speaking at a Barclays fireside chat hosted by analyst James Gordon, Chief Fi
How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build
Genmab’s analyst fair value estimate has been adjusted from DKK 2,182.25 to DKK 2,237.63, while some bullish price targets now cluster in the DKK 2,400 to DKK 2,500 range and around US$40 to US$41.50. These shifts reflect fresh reactions to earnings, product updates, acquisitions and the debate over how 2026’s heavy catalyst calendar could affect longer term earnings power. Read on to see how you can track this evolving narrative and what to watch as analyst views continue to adjust. Analyst...
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls